| Rupal Jayprakash Shah, MD | |
|
3400 Civic Center Blvd, West Pavilion 1st Fl, Philadelphia, PA 19104-5127 | |
| (215) 662-3202 | |
| Not Available |
| Full Name | Rupal Jayprakash Shah |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 19 Years |
| Location | 3400 Civic Center Blvd, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396937264 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD436473 (Pennsylvania) | Primary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | MD436473 (Pennsylvania) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ucsf Medical Center | San francisco, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ucsf Medical Group Business Services | 3779497870 | 1064 |
| Regents Of The University Of California | 4284547274 | 563 |
| University Of California San Francisco | 4486567229 | 1298 |
News Archive
Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.
Agilent Technologies Inc. today announced that Harvard Medical School has selected Agilent's 700-MHz Ultra-High Field Nuclear Magnetic Resonance spectrometer for biomolecular research applications.
Addition of lapatinib to trastuzumab improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research.
According to the American Foundation for Suicide Prevention, suicide is the 10th leading cause of death in the U.S., with over 1.4 million suicide attempts recorded in 2018.
Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
› Verified 3 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881763597 PECOS PAC ID: 4284547274 Enrollment ID: O20031106000389 |
News Archive
Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.
Agilent Technologies Inc. today announced that Harvard Medical School has selected Agilent's 700-MHz Ultra-High Field Nuclear Magnetic Resonance spectrometer for biomolecular research applications.
Addition of lapatinib to trastuzumab improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research.
According to the American Foundation for Suicide Prevention, suicide is the 10th leading cause of death in the U.S., with over 1.4 million suicide attempts recorded in 2018.
Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
› Verified 3 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.
Agilent Technologies Inc. today announced that Harvard Medical School has selected Agilent's 700-MHz Ultra-High Field Nuclear Magnetic Resonance spectrometer for biomolecular research applications.
Addition of lapatinib to trastuzumab improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research.
According to the American Foundation for Suicide Prevention, suicide is the 10th leading cause of death in the U.S., with over 1.4 million suicide attempts recorded in 2018.
Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
› Verified 3 days ago
| Entity Name | Ucsf Medical Group Business Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.
Agilent Technologies Inc. today announced that Harvard Medical School has selected Agilent's 700-MHz Ultra-High Field Nuclear Magnetic Resonance spectrometer for biomolecular research applications.
Addition of lapatinib to trastuzumab improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research.
According to the American Foundation for Suicide Prevention, suicide is the 10th leading cause of death in the U.S., with over 1.4 million suicide attempts recorded in 2018.
Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rupal Jayprakash Shah, MD 3400 Civic Center Blvd, West Pavilion 1st Fl, Philadelphia, PA 19104-5127 Ph: (215) 662-3202 | Rupal Jayprakash Shah, MD 3400 Civic Center Blvd, West Pavilion 1st Fl, Philadelphia, PA 19104-5127 Ph: (215) 662-3202 |
News Archive
Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.
Agilent Technologies Inc. today announced that Harvard Medical School has selected Agilent's 700-MHz Ultra-High Field Nuclear Magnetic Resonance spectrometer for biomolecular research applications.
Addition of lapatinib to trastuzumab improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research.
According to the American Foundation for Suicide Prevention, suicide is the 10th leading cause of death in the U.S., with over 1.4 million suicide attempts recorded in 2018.
Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.
› Verified 3 days ago
Philippe Olivier Szapary, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3400 Civic Center Blvd, East Pavilion, 2nd Floor, Philadelphia, PA 19104 Phone: 215-615-4949 | |
Dr. Jamie L. Garfield, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-5864 Fax: 215-707-6867 | |
Maria Esther Escorcia De Leon, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-1622 Fax: 215-707-0943 | |
Cherag Daruwala, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2301 E Allegheny Ave, Suite 190b, Philadelphia, PA 19134 Phone: 215-926-3120 Fax: 215-926-3123 | |
Dr. Robert Burke, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 51 N 39th St, Philadelphia, PA 19104 Phone: 215-662-9436 Fax: 215-243-3208 | |
Eva Hassan Alsheik, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 219 N Broad St, 5th Floor, Philadelphia, PA 19107 Phone: 215-762-6071 | |
Dr. Jason Thomas Ackrivo, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3400 Spruce St, Philadelphia, PA 19104 Phone: 215-614-0871 |